Background: A comprehensive assessment of the risk-benefit profile of biologic agents in psoriasis is lacking. We conducted a network meta-analysis of randomized trials on biologic agents in psoriasis.
INTRODUCTION
Psoriasis, whenever involving a sizable body surface of a patient or being associated with arthritis, represents a major cause of morbidity worldwide [1] . Despite the limited advancements in the management of this condition which occurred in prior decades, novel treatments have been tested in the last years, with very favorable results for many biologic agents with disease modifying properties [2] . These includes agents which block tumor necrosis factor-(TNF-), as well as antilymphocyte T, anti-interleukin-12/23 (IL-12/23), and anti-interleukin-17 (IL-17) agents. Clinicians wishing to decide which treatment is better, in terms of safety or efficacy, are however facing a major challenge, as most studies were placebo-controlled trials with moderate size, and few meaningfully powerful comparative effectiveness and safety trials are available [3] . Systematic reviews incorporating pairwise and network meta-analysis may successfully synthesize the evidence base on a specific clinical issue, providing precise overall and interaction effect estimates [4] . Indeed, three mixed treatment comparisons have already been reported on this topic [5] [6] [7] , but were limited by the too narrow focus on a specific subset of studies, or the lack of inclusion of the many trials which have been published in the last few years. Specifically, Migliore et al. included four trials [6] , Lin and colleagues 17 [5] , and Reich et al. 20 [7] .
Meta-Analyses (PRISMA) guidelines [8] . All reviewing activities were performed independently by two experienced reviewers, with divergences solved after consensus.
Search
Pertinent studies were searched in MEDLINE/PubMed according to Biondi-Zoccai et al's string for controlled clinical trials [9] , and exploiting the following terms: abatacept; adalimumab; anakinra; briakinumab; brodalumab; certolizumab; etanercept; golimumab; infliximab; ixekizumab; psoriasis; rituximab; tocilizumab; ustekinumab (see also Appendix for the detailed strategy). In addition, CENTRAL, Google Scholar, and Scopus were searched for suitable studies. The search was last updated on September 21, 2013 . No language restriction was enforced.
Selection
Initially retrieved citations were screened at the title/abstract level and then retrieved as full texts if potentially pertinent. Full reports were included if reporting on patients with psoriasis receiving biologic agents, and included in a randomized trial. Studies were excluded if not based on random allocation, duplicates, lacking details on clinical efficacy or safety outcomes, including anti-IL-17 agents (whose evidence base is still preliminary and are still under preregistration investigation), or focusing on efalizumab (which was discontinued due to the risk of fatal brain infarctions associated with its usage) [10] .
Abstraction and Validity Appraisal
Key baseline, procedural and outcome data were systematically retrieved, focusing specifically on efficacy and safety outcomes. As efficacy outcomes, we focused on the binary rates of reduction 75% in the Psoriasis Area and Severity Index (PASI75), and improvement 20% in the American College of Rheumatology core set of outcomes (ACR20), both at the longest available follow-up. As safety outcomes, we focused on serious adverse events (SAE), and adverse events (AE), both at the longest available follow-up. The internal validity of shortlisted studies was appraised focusing on design features, including study setting, blinding, and type of comparator.
Analysis
Categorical variables are described as counts or %. Pairwise meta-analysis was performed with RevMan (The Cochrane Collaboration, Copenhagen, Denmark) within a frequentist framework with the DerSimonianLaird random-effect model, pooling risk ratios (95% confidence intervals). Conversely, network metaanalysis was performed with WinBUGS (MRC Biostatistics Unit, Cambridge, UK) within a Bayesian framework with a random-effect binomial likelihood hierarchical model, sampling effect estimates with Markov chain Monte Carlo (MCMC) methods, computing risk ratios (95% credibility intervals) and probability of being the best treatment for each agent [11] . These analyses were based on a 50,000-run training set and a 150,000-run inferential set. Convergence was appraised with the Gelman-Rubin statistic. Model fit for Bayesian inference was appraised with the deviance information criterion (DIC), comparing random-effect and fixed-effect models reported in detail by Greco et al. [12] .
Using RevMan within a frequentist framework, kairwise heterogeneity was appraised using chisquared test, and inconsistency with I 2 . Consistency between direct estimates (which are directly based on head-to-head randomized comparisons) and indirect estimates (which rely on the exchangeability assumption) was instead appraised by comparing consistency and inconsistency models as computed with WinBUGS in a Bayesian framework [12] . Specifically, consistency models assume that no substantial variation in treatment effect between pairwise contrasts, whereas an inconsistency model does not assume underlying similarity of direct and indirect effects. Accordingly, comparing results stemming from consistency and inconsistency models is a suitable test of the exchangeability and consistency assumptions [13] . Small study effects were appraised with funnel plot inspection using RevMan within a frequentist framework.
RESULTS

Reviewing Process
From an initial set of 21,475 citations, 21,286 were excluded at the title/abstract screening stage ( Figure  1) . Thereafter, 189 articles were appraised as full reports, leading to the inclusion of a total of 52 trials and 17,617 patients, including 9 different biologic agents (references of included and excluded studies are available from the corresponding author upon request). The main reason for exclusion of full reports was duplication of trial data, followed by observational design, and meta-analysis as study type.
Evidence Base
The included studies compared, with variable assortments, placebo and 11 different pharmacologic agents: abatacept, acitretin, adalimumab, alefacept, briakinumab, certolizumab, etanercept, golimumab, infliximab, methotrexate, and ustekinumab ( Figure 6A ).
Network Meta-Analysis
Network meta-analysis, exploiting both direct and indirect agent-level comparisons, showed that several biologic agents provided higher PASI75 rates than placebo ( 
DISCUSSION
This review has several key implications: first, biologic therapy for moderate to severe psoriasis or psoriatic arthritis is associated with clear and clinically meaningful benefits in terms of psoriasis and arthritis burden in comparison to placebo; second, adverse events are increased, at least by some classes of biologic agents, but the overall balance is not clearly in favor of placebo given the occurrence of diseaserelated adverse events when the condition is not adequately controlled; third, remarkable differences in safety and efficacy profile are evident between the different classes of biologic agents and even between individual agents in the same class; thus, biologic therapy should be considered in the management of moderate to severe psoriasis or psoriatic arthritis, with class and agent choice based on the specific patient risk profile, clinical history, and goal of therapy. The burden of psoriasis is very important and not limited to few developed countries. Given its chronicity and phasicity, psoriasis may prove clinically challenging, especially when associated with arthritis or involving a large part of the body surface or the nails [14] . Given the improvement in our understanding of its pathophysiology, including the preminent role of inflammation, and the setbacks of topical therapy or phototherapy in severe cases, there is an ongoing quest for effective and safe systemic therapies for psoriasis. This momentum has lead to the successful testing of several anti-inflammatory agents, and, subsequently, immune-modulating agents, typically called biologics [15] .
Biologics belong to four broad categories, which correspond to the main inflammation mechanisms involved in this condition [16] [17] [18] [19] . Agents blocking the IL-12/23 pathway, such as briakinumab and ustekinumab, anti-IL-17 agents, such as brodalumab, ixekinumab, and secukinumab, drugs which have inhibitory effects on T lymphocytes, such as abatacept and alefacept, and anti-TNFagents, such as adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Our work, which comprehensively pools the evidence on biologic agents and compare them versus placebo, acitretin, and methotrexate, has important implications for practicing physicians and patients. Under the hypothesis that each agent has, even within the same class, a unique and individual risk-benefit profile, we suggest that the most effective agent in patients with moderate to severe plaque psoriasis is golimumab, whereas the most effective one in subjects with psoriatic arthritis is infliximab. Conversely, severe adverse events were fewer with golimumab, while the occurrence of any adverse event was less likely with abatacept. However, differences between individual agents were often not large and credible. Nonetheless, decision-makers should bear in mind these agent-specific risk-benefit profiles to maximize response rates and minimize complications of systemic therapy for psoriasis.
This work is not the first in its kind, but actually builds upon prior network meta-analyses, yet substantially expanding their findings. Indeed, Lin et al. already showed, analyzing 17 trials on moderate to severe plaque psoriasis and 5 biologic agents, that ustekinumab was more efficacious than adalimumab, etanercept, and alefacept, but not infliximab [5] . Migliore and colleagues focused instead only on anti-TNF-agents for psoriatic arthritis, including four trials with 820 patients. In this very specific setting, they reported that etanercept was the best agent in terms of rates of ACR20 [6] . Reich et al. pooled instead a total of 20 trials, albeit 4 of them focusing on efalizumab, which was discontinued for fatal toxicity. They suggested, in keeping with our own results, that infliximab was the drug with the most favorable efficacy profile, followed by ustekinumab, adalimumab, and etanercept [7] . Most recently, Schmitt and colleagues pooled data from 48 trials and 16,696 patients, finding that infliximab was the most effective agent for moderate-to-severe psoriasis, but limited their scope to efficacy endpoints only [20] . Finally, our findings should also be put into the cost-effectiveness context laid out in 2008 by Nelson et al., who suggested by pooling 14 trials that adalimumab and infliximab were the most cost-effective biologic agents for the treatment of psoriasis [21] .
This work has several limitations, and shares most of the drawbacks typical of systematic reviews, pairwise meta-analyses, and network metaanalyses/mixed treatment comparisons [11, 12, 22] . In addition, we mainly relied on subjectively assessed endpoints, as both therapeutic response in plaque psoriasis or psoriatic arthritis is typically based on such outcomes. In addition, cross-over phases were excluded, limiting statistical precision and follow-up duration [23] . Notably, differences in trial phases and follow-up durations may have confounded the overall study results. Some effect estimates were based only on few studies (for instance only 1 trial reported on golimumab). Accordingly, the robustness and external validity of our results may vary depending on the specific agent analyzed and its corresponding evidence base. Appraisal of specific and rarer adverse effects of these agents (e.g. myocardial infarction, lifethreatening infection or cancer) was beyond the scope of this review [24, 25] . Finally, biologic agents can be combined with other anti-inflammatory drugs, such as methotrexate, acitretin, or cyclosporine. Other combinations include those with phototherapy or other topical treatments. Network analyses of these treatment approaches was beyond the scope of the present review and merits further investigations in the future.
In conclusion, biologic agents provide significant clinical benefits in patients with moderate to severe psoriasis or psoriatic arthritis. There are differences in the efficacy and safety profile for each agent, and clinicians should bear in mind these features to maximize safety and efficacy in the individual patient.
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